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NGALIn recent years there has been growing interest in the development of new diagnostic tools and particularly
in laboratory tests for the identiﬁcation of heart failure (HF) patients. Because of the rise in HF occurrence, it
is necessary to use simple and reliable method to recognize those patients at risk before the onset of the clin-
ical symptoms. To date HF diagnosis remains difﬁcult: its symptoms and signs are often non speciﬁc as well as
being poor sensitive indicators for HF severity. Throughout the last 10 years published literature has
highlighted a boom in the use of biomarkers for HF. Both B-type and N-terminal pro-B-type natriuretic pep-
tides have demonstrated speciﬁc role in heart failure diagnosis, as well as risk assessment. A single determi-
nation of BNP at any time during the development of chronic heart failure (CHF) provides a clinically useful tool
to establish the outcome. Renal dysfunction is often associated with heart failure and predicts adverse clinical
outcomes. Many studies have recently suggested the clinical use of serum neutrophil gelatinase‐associated
lipocalin (NGAL) levels in patients admitted to the hospital for acute HF can be used to estimate the risk of
early worsening renal function. This could be potentially applied in clinical practice for early identiﬁcation of
renal dysfunction development in patients with HF. NGAL levels appear also to predict renal dysfunction in pa-
tients with chronic HF and preserved renal function. For all these reasons, BNP and NGAL are two emerging tools
useful for diagnosis and prognosis inHF. The combination of two laboratory biomarkers could potentially identify
patients with more elevated risks of both cardiac hemodynamic impairment and kidney dysfunction.
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Heart failure has a signiﬁcant impact on the health care system,
and its occurrence is ever increasing in the elderly. It is generally es-
timated that HF currently affects 0.4%–2% of the European population
[1]. In United States approximately 5,8 million patients were affected
by HF [2]. It is well known that the incidence of HF rises substantiallydicine andMetabolic Diseases,
53100 Siena, Italy. Tel.: +39
rights reserved.with age. The prevalence of HF in people over 65 years of age has
been reported to be 6%–10%. This data shows that heart failure is a
chronic disease that affects a large part of health care resources [3].
Before 1990, as many as 60 to 70% of patients died within 5 years
of the diagnosis of systolic heart failure, and hospitalization as a con-
sequence of the exacerbation of symptoms was frequent. Moreover
in recent years neither there has been no observed improvement,
neither in outcome nor in rehospitalization [4].
The great variability that characterizes HF syndrome depends on
the heterogeneity in patient population and multiple etiologies [5].
There are big differences between patients in terms of cardiac or
non cardiac morbidity and genetic characteristics. This is the primary
consideration approaching patients with HF, because the pathophys-
iological process varies between cases [6]. Many clinical trials in acute
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incorrect classiﬁcation of the patients enrolled. The natural history
and treatment strategies are often the same, however clinical approach
and strategy should be speciﬁcally addressed [7]. Early diagnosis is very
important for therapy optimization and to improve the outcomes. The
ability to recognize cardiac insufﬁciency at an early stage before signs
and symptoms manifest, depends on the speciﬁcity, sensibility and ac-
curacy of the tools used. For this reason, there is an increasing interest
in the development of new biomarkers and a great number of laborato-
ry tests have recently been put forward for early LV process remodeling
identiﬁcation.
Each biomarker needs to reach its diagnostic and prognostic accu-
racy. Morrow and de Lemos have deﬁned three major criteria a bio-
marker should fulﬁll to be clinically useful: 1 — accurate, repeated
measurements must be available at a reasonable cost and with short
turnaround times; 2 — the biomarker must provide information that
is not already available from a careful clinical assessment; 3 —
knowing the measured level should aid in medical decision making
[8]. One of the biggest hopes for utilizing biomarker testing is to
determine the level of disease severity as a means to triage medical
decisions as well as to monitor their responses. Moreover each bio-
marker should include some preconditions: some characteristics are
linked to chemical detection (in vivo and in vitro stability, low cost,
sensitivity, international standardization reference tested for gender
and age), some others need to respond to clinical practice (good diag-
nostic and prognostic accuracy, useful in therapy management, and
favorable cost-effectiveness ratio) [9] (Fig. 1). In clinical practice it
is hard to ﬁnd speciﬁc biomarkers containing all these characteristics,
although several classes of biomarkers are currently accepted in the
ﬁeld of heart failure [10]. An approach with multiple biomarkers
could help to classify patients with high risk of clinical worsening and
in need of hospitalization and intensive care. BNP and NGAL are two
emerging tools useful for diagnosis and prognosis in HF. Hereunder
we describe their clinical use and their ﬁeld of application on the basis
of past and recent literature.
2. Natriuretic peptides in heart failure
The most important biomarker for heart failure are brain natriuretic
peptide (BNP) and its precursor NT proBNP. B-type natriuretic peptide
is a member of a class of hormones that regulate blood pressure. BNP
and its amino-terminal cleavage equivalent N-terminal prohormone
brain natriuretic peptide (NT-proBNP) originate from a pre-proBNP
hormone of 134 residues that is cleaved to yield a 108 amino acid
intracellular pro-hormone, proBNP108; from proBNP108, BNP and
NT-proBNP are released in varying amounts. BNP is synthesized in
the heart as a reaction to cardiac wall distension, and stretching andLow cost, cost
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Fig. 1. Clinical and biochemical features for an ideal biomarker.neurohormonal activation. BNP leads to natriuresis and vasodilatation
activation with associated inhibition of the renin angiotensin system
and adrenergic activity. BNP plays an important regulatory role in
response to acute increases in ventricular volume by opposing the
vasoconstriction, sodium retention, and antidiuretic effects of the acti-
vated renin–angiotensin–aldosterone system.
Several studies demonstrated that increased levels of circulating
BNP are found in early stages of HF. The level of BNP in the blood con-
tinues to increase as the HF disease advances. Reports have indicated
that there is a relationship between the severity of the clinical signs
and symptoms of HF and BNP concentrations. BNP is also useful in
screening asymptomatic patients at risk of developing HF (elderly
patients with diabetes, hypertension or asymptomatic coronary artery
disease). Blood BNP concentrations represent an independent assess-
ment of ventricular function and could be employed as a biomarker
for preclinical ventricular dysfunction [11].
Recently natriuretic peptide (NP) measurement has been included
in the HF diagnosis algorithm (Table 1). A BNP level below 100 pg/ml
exclude HF diagnosis; values of BNP between 100 and 400 pg/ml, re-
quire imaging techniques to conﬁrm heart failure diagnosis. On the
contrary BNP values above 400 pg/ml are associatedwith high accuracy
and a worsening outcome. Values of BNP between 100 and 400 pg/ml
represent a grey zonewhere it is not possible to ascertain their diagnostic
role accurately and to predict a value for this biomarker [12]. In patients
in the emergency department (ED) for acute dyspnea the measurement
of BNP levels can distinguish cardiac from pulmonary causes: patients
with heart failure have higher peptide levels, as opposed to patients
with dyspnea caused by respiratory diseases [13,14]. The REDHOT
study on patients admitted in ED with shortness of breath, clarify
the role of BNP values in the diagnosis of heart failure and in the predic-
tion of the future outcome [15]. Recently NT pro BNP has been studied
in the emergency department to establish the severity of both disease
and outcome, conﬁrming that its measurement is associated with
good classiﬁcation of patient care [16]. Introduction of NT-proBNP test-
ing for heart failure in the ED setting reduces the time of discharge.
NT pro BNP is strongly linked to subsequent utilization of hospital
resources [17].
A recent report investigated the applicability of urinary B-type
natriuretic peptide levels in the diagnosis of heart failure compared
to plasma BNP levels. In the detection of HF, the measurement of
urinary BNP offers similar results, besides having the advantage of
being a noninvasive test (Table 2) [18].
BNP measurement is also validated by hemodynamic studies. BNP
accurately reﬂects ventricular ﬁlling pressure, pulmonary pressure
and is correlated inversely with cardiac output [19]. Iwanaga et al.
observe that plasma BNP levels reﬂect left ventricular end-diastolic
wall stress (EDWS) more than they do left ventricular end-diastolicTable 1
American Heart Association recommendation (2005 and 2009) for the use of natriuretic
peptides in HF diagnosis and risk prediction.
2009 focused update: ACCF/AHA
Guidelines for the diagnosis and management of heart failure in adults
Class IIa
2005 guideline recommendations
Measurement of BNP can be useful in the evaluation of patients presenting in the ur-
gent care setting in whom the clinical diagnosis of HF is uncertain.
(Level of evidence: A)
2009 focused update recommendations
Measurement of natriuretic peptides (BNP and NT-proBNP) can be useful in the eval-
uation of patients presenting in the urgent care setting in whom the clinical diagnosis
of HF is uncertain. Measurement of natriuretic peptides (BNP and NT-proBNP) can be
useful in risk stratiﬁcation.
(Level of evidence: A)
Comments
Modiﬁed recommendation (added a caveat on natriuretic peptides and their role as
part of total evaluation, in both diastolic and systolic dysfunctions).
Table 2
BNP and NTpro-BNP clinical trials with associated cut off in acute heart failure diagnosis.
Author Year Study design Cut-off BNP or NT-pro BNP Findings
Morrison,
LK
[14]
2002 Evaluate how a rapid assay for BNP levels could
help physicians to differentiate cardiac from
pulmonary causes of dyspnea in ED.
A BNP value of 94 pg/ml had a sensitivity of
86%, speciﬁcity of 98% and an accuracy of 91%
for differentiating CHF from pulmonary disease.
Patients with CHF had BNP levels signiﬁcantly
higher than the group of patients with a ﬁnal
diagnosis of pulmonary disease. Rapid testing
of BNP in the ED should help differentiate
pulmonary from cardiac etiologies of dyspnea.
Maisel, A
[15]
2004 Examine the relationships among BNP levels
within the diagnostic range, perceived congestive
heart failure severity, clinical decision making,
and outcomes of the CHF patients presenting to
emergency department (ED).
Entrance criteria included a BNP level >100 pg/ml.
Admitted patients were divided into two groups
based on BNP levels above and below 200 pg/ml
to study differences in outcome rates.
The BNP levels can predict future outcomes and
thus may aid physicians in making triage decisions
about whether to admit or discharge patients.
Emerging clinical data will help further reﬁne
biomarker-guided outpatient therapeutic and
monitoring strategies involving BNP.
Mueller, C
[13]
2004 Prospective, randomized, controlled study
presenting to the ED with acute dyspnea: assigned
to a diagnostic strategy involving the measurement
of BNP, compared to the standard method.
Discharge time and total cost of treatment were the
primary end points.
1) BNP level of 100 pg/ml to separate dyspnea
caused by HF from other causes of dyspnea. 2) BNP
level below 100 pg/ml the diagnosis of HF was
considered unlikely. 3) BNP peptide level of more
than 500 pg/ml, HF was considered the most likely
diagnosis. 4) BNP levels between 100 and 500 pg/ml,
the protocol recommended the use of clinical
judgment and possible further diagnostic test.
Used in conjunction with other clinical information,
rapid measurement of BNP in the emergency
department improved the evaluation and treatment
of patients with acute dyspnea and thereby reduced
the time of discharge and the total cost of treatment.
Rutten, JH
[17]
2008 477 patients presenting dyspnea were randomized
for either rapid measurement or no measurement
of NT-proBNP. Time to discharge and costs related
to hospital admission were primary end points.
Bootstrap analysis was used for comparison of costs
and 30-day mortality between the NT-proBNP and
control group.
For ruling out HF, cutoff values of 93 pg/mL in male
and 144 pg/mL in female patients were used. For
ruling in HF, a cutoff value of 1017 pg/mL was used.
Introduction of NT-proBNP testing for heart failure
in the ED setting reduces the time to discharge and
is associated with a cost reduction trend.
Song, J
[18]
2011 Urinary and plasma BNP levels weremeasured on
160 patients with HF classiﬁable into NYHA stages
I, II, III, or IV and 30 healthy control subjects. The
heart function of each patient was examined by
echocardiography.
The optimal cutoff value for urinary BNP was
36.5 pg/ml.
Urinary and plasma BNP levels among patients in
the HF group were signiﬁcantly higher than those
in the control group. Urinary BNP levels were
correlatedwith plasma BNP levels and NYHA grades
of HF and were negatively correlated with LVEF.
Luchner, A
[16]
2012 Prospective randomized, multicentre trial
conducted in patients>65 years old. NT-proBNP
as a marker of heart failure and other cardiac
diseases was assessed. Primary endpoint was
hospital admission; secondary endpoints were
intermediate/intensive care unit (IMC/ICU)
admission, length of stay, re-hospitalization
and death, or re-hospitalization.
Was considered three different groups of patients
withNT-proBNPb150 pg/mL(low),withNT-proBNP
between 150 and 1800 pg/mL (intermediate), with
NT-proBNP>1800 pg/mL (high).
Knowledge of NT-proBNP had no signiﬁcant effect
on the primary endpoint hospital admission and
the secondary endpoints. However patients with
high open NT-proBNP (>1800 pg/mL) were more
likely to be admitted to the hospital and IMC/ICU
whereas patients with low open NT-proBNP
(b150 pg/mL) were less likely to be admitted
compared with patients with blinded NT-proBNP.
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tients with diastolic HF. The relationship of left ventricular EDWS to plas-
ma BNP may provide a better fundamental understanding of the
interindividual heterogeneity in BNP levels and their clinical utility in di-
agnosis and management [20].
BNP is also a useful follow up test and to assess prognosis of patients
with HF. Elevated plasma BNP levels upon admission are a valid inde-
pendent predictor of in-hospital mortality in acute decompensated HF
with preserved or reduced systolic function, which don't depend on
other clinical or laboratory variables [21]. Serial measurements of BNP
in the chronic outpatient setting appear to convey additional prognostic
value to relevant adverse outcomes, including death or destabilization
of CHF requiring hospitalization, and they are thus recommended in clin-
ical practice. Several studies that used natriuretic peptides pre-discharge
indicate that BNP levels appear to be the strongest predictors for identi-
fying subsequent death or hospital admission within 6 months [22,23].
The dosage of BNP providesmore prognostic information thanother ne-
crosis biomarkers as well as imaging indexes like ejection fraction and
shortening fraction. In the Australia–New Zealand Heart Failure Group
Trial patients with chronic HF and reduced systolic function levels of
NT pro BNP above the average were linked to an increased risk of new
decompensatedHF events,which all causedmortalitywithin 18 months
of the follow up [24]. In the Valsartan Heart Failure (Val-Heft) trial,
which included 5010 patients with mild to moderate chronic HF receiv-
ing recommendedmedical therapy; an increment of 500 ng/L above the
baseline concentration of NT pro BNP carried an increase in adjusted risk
of 3.8% for mortality and 3.0% for hospitalization for HF [25].Although NP have been useful in HF diagnosis and risk prediction,
some confusing factors could inﬂuence the levels of NP. Age, race, obe-
sity, and renal dysfunction may complicate the clinical interpretation
of circulating BNP levels in patients with chronic and stable congestive
heart failure. Obesity may reduce diagnostic accuracy of B-type natri-
uretic peptide; the BNP levels were lower in obese patients hospital-
ized for HF compared to non obese patients [26]. In obese patients,
the determination of BNP levels reduced time on onset of the appropri-
ate treatment. Obese patients showed half the short and the long term
mortality of non obese patients [27]. Also body mass index inﬂuences
the selection of cut-points for BNP in diagnosing acute HF and in order
to preserve sensitivity it is necessary to place a lower cut-off in severely
obese patients [28]. This way it's possible to maintain high standard
in the prediction of serious symptoms, impaired haemodynamics, and
higher mortality at all levels of BMI. Redﬁeld et al. conﬁrm the impact
of age and sex on BNP observed in subjects without cardiovascular dis-
ease, therefore NP measurement would be used to take into account
discriminatory values adjusted for sex and age [29]. It has been demon-
strated that age increases the level of circulating BNP; this is related to
the decline in myocardial function, myocardial ﬁbrosis with diastolic
dysfunction and the reduction in clearance of natriuretic peptides typi-
cal of senescence. Race is another factor that could inﬂuence plasma
BNP levels; for each NYHA class perception, Hispanic and black races
have a higher level compared to the Caucasian population [30].
Beside physiologic factors, several inﬂammatory and systemic dis-
eases can also affect NP values. Many studies demonstrated the impact
of renal insufﬁciency onnatriuretic peptides independently fromcardiac
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also on the duration of the disease [31]. Cruz et al. calculated that in
the presence of this associated condition, BNP levels increased of 1/3
compared to a patientwith normal renal function [32]. Anemia is another
condition frequently associated with more advanced HF stages and its
correction could reduce natriuretic peptide levels [33]. Another limitation
in clinical practice concerns the time of measurement that reﬂects vol-
ume status: NP is released by increased volume load and wall stretch,
and is inﬂuenced by systemic idro-saline retention. After treatment
with drugs of proven efﬁcacy, there is a progressive reduction of BNP,
considered to be evaluation of congestion. Finally several cardiac factors,
even in the absence of increased ﬁlling pressure and straight forward HF,
can cause NP alteration: increased LV mass, reduced right ventricular
function, mitral valve disease, high pulmonary pressure for primitive or
secondary respiratory disease, pulmonary embolismand atrialﬁbrillation
are all causes of potential NP increase. NPmeasurement has high sensitiv-
ity but low speciﬁcity and laboratory tests need to be conﬁrmed by a
clinical and traditional diagnostic screening process.
3. Natriuretic peptides and imaging
After traditional ﬁrst line evaluations (ECG, thorax radiography and
clinical examination), echocardiography is the technique recommended
for patients affected by heart failure, thanks to its easy availability and
reproducibility. Echocardiography still remains an important tool for
the diagnosis of left ventricular (LV) dysfunction;many authors suggest
a complementary approach for echocardiography and BNP in patients
with HF symptoms. This way of proceeding improves diagnostics and
the classiﬁcation of patients [34]. Contrariwise Maisel et al. suggest
that the use of BNP assay reduces the need for echocardiography in
many patients with left ventricular dysfunction [35]. Moreover, for
patients hospitalized after HF diagnosis, for the prediction of future
cardiac death or rehospitalization for CHF, BNP assay in pre-discharge
is more effective than doppler echocardiographic examination [36].
BNP and NT-proBNP levels correlate positively with left ventricular
dimension volumes and mass in a variety of populations. However,
there is only a mild correlation between BNP and systolic parameters
such as left ventricular ejection fraction (LVEF) and stroke volume
[37]. In a meta-analysis, Latour-Perez et al. showed that NP had a wide
range of correlation ranging from high to low values. This range could
be linked to different population characteristics and to the severity
of systolic dysfunction. BNP and NT proBNP have particularly positive
predictive values when it comes to more severe systolic ventricular
dysfunction. BNP is linked to indexes of ﬁlling pressure, including
transmitral early ﬁlling velocity (E) and early diastolic annular velocity
TDI E\E′. However, a single value for BNP and NT pro-BNP is unable to
provide a reliable estimation of ﬁlling pressure across individuals,
although very low levels retain strong negative predictive values for el-
evated ﬁlling pressure. BNP is correlated with restrictive diastolic pat-
tern and pulmonary hypertension with right systolic dysfunction. NP
levels are also higher in patients with left ventricular hypertrophy. The
diagnosis or exclusion of suspected heart failure, both systolic or
diastolic, can be performed accurately by echocardiographic measure-
ment of LV longitudinal systolic function [38]. Moreover, BNP is strongly
linked with ventricular longitudinal systolic function. BNP and NT
pro-BNP also reﬂect left atrial size, correlating positively with left atrial
volume. However this relation appears diminished in patients with
decompensated HF and in subjects with advanced systolic HF.
High levels of BNP and NT pro BNP are correlated with the level of
diastolic dysfunction. Most patients with HF have both systolic and
diastolic LV dysfunctions, but in some cases the syndrome can occur
with isolated systolic or diastolic dysfunction. Heart failure with pre-
served left ventricular ejection fraction (LVEF) involves almost 50% of
patients with HF [39]. In clinical practices it is not easy to distinguish
HF with preserved LVEF from heart failure with reduced EF on
the basis of traditional diagnostic tools. HF with preserved LVEF ischaracterized by a non-dilated, usually hypertrophied left ventricle
in which LVEF is preserved at rest. The parameters of LV relaxation
and ﬁlling pressure are markedly unbalanced. Invasive measurement
is the standard reference for establishing LV end diastolic ﬁlling pres-
sure and pulmonary pressure. In this setting Doppler and tissue
Doppler study are the most reliable and accurate methods. Although
diastolic dysfunction and consequent ﬁlling pressure alteration can
be recognized by this examination, there is a grey zone in which it
is not possible to identify patients with elevated ﬁlling pressure. The
diagnosis in these patients is facilitated by NP measurement [40,41].
Lubien et al. successfully demonstrated this with BNP level over
200 pg/ml and not clear eco Doppler study [42]. The two-step approach
of eco Doppler and NP measurement is able to recognize community
patients with increasing risk of developing diastolic impairment and
HF syndrome development [43].
Bistola et al. have found a prognostic value in the evaluation
of right ventricular tissue Doppler imaging (RV TDI) combined with
increased plasma BNP. They enrolled patients with advanced heart
failure secondary to ischemic or idiopatic dilated cardiomiopathy.
RV TDI and high levels of BNP predict adverse cardiac outcomes in
advanced CHF [44]. As a consequence of this quality, some authors
have suggested the use of echocardiographic multi-parameter score
(EMPS) based on systolic and diastolic function, left ventricular chamber
remodeling, valvular lesions, pulmonary arterial pressure, and regional
wall-motion abnormalities in combination with NP measurement, to
better detect LV global function and the severity of heart failure [34].
Findings resulting from a comparison between BNP and LV
remodelling evaluated by cardiac magnetic resonance (CMR) con-
ﬁrmed that the hormone is related to microvascular obstruction
(MO), left ventricular function, myocardial perfusion, myocardial
scar and infarct size. Bruder et al. have found a strong correlation
between the extent of delayed enhancement (DE), microvascular
obstruction in contrast-enhanced MRI and the plasma level of
NT-pro-BNP in patients with acute myocardial infarction. The associ-
ation of biomarker and delayed enhancement highlights the strong
prognostic impact of contrast-enhanced CMR after acute myocardial
infarction. This data is useful for the evaluation of patients who
could develop HF and ventricular enlargement [45]. The prognostic
value of N-terminal pro-brain natriuretic peptide with CMR imaging
parameters of cardiac function and infarct size was assessed in pa-
tients with ST-segment elevation myocardial infarction. Compared
to CK-MB, troponin T, CRP, and creatinine clearance, NT-pro-BNP
level>260 pg/ml is a strong independent predictor of left ventricular
ejection fraction in patients with non anterior wall myocardial infarc-
tion. NT-pro-BNP could be useful in early risk stratiﬁcation of these
patients [46]. Mayr et al. conﬁrmed the correlation between NT-pro
BNP and acute and chronic infarct size, EF and systolic wall tension
after MI assessed by CMR [47]. Furthermore NT-proBNP levels strong-
ly correlate with left ventricular wall stress and sphericity index [48].
BNP levels were observed in patients who underwent ECG-gated
SPECT and echocardiography to assess systolic and diastolic function.
This study evaluated left ventricular functional parameters calculated
using quantitative electrocardiography (ECG)-gated myocardial per-
fusion single photon emission computed tomography (QGS). In addi-
tion to LV systolic parameters, diastolic parameters were compared
with those by ultrasound echocardiography (UCG) and also with
plasma B-type natriuretic peptide (BNP) concentrations. LV systolic
and diastolic dysfunctions evaluated by QGS are strongly correlated
with that by UCG or BNP. The QGS functional parameters give new
additional information in patients at risk of developing cardiac failure
[49].
BNP was compared with PET scanning in patients with chronic
heart failure and ischemic cardiomyopathy. Ischemia, hibernation,
and myocardial scarring were evaluated and it was found that a de-
crease in BNP value was associated with extensive myocardial scarring
[50].
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neuthrophil gelatinase associated lipocalin (NGAL) is a member of
the lipocalin superfamily of proteins. These are typically small proteins
characterised by their ability to bind small, hydrophobic molecules in a
structurally conserved pocket, and to formmacromolecular complexes.
Human NGAL is a protein which can be covalently bound to gelatinase
from neutrophils through a single intermolecular disulﬁde bridge poly-
peptide chain of 178 amino-acid residues with a calculated molecular
mass of 22 kDa, but glycosylation increases its apparent molecular
mass to 25 kDa. NGAL has many synonyms: it is also known as neutro-
phil lipocalin (NL or HNL for the human form), lipocalin 2, oncogene
protein, 24p33 or uterocalin in the mouse, and neu-related lipocalin.
In neutrophils and urine it occurs as a monomer, with a small percent-
age of dimer and trimer, and it also occurs as a complex with 92-kDa
human neutrophil type IV collagenase, also called gelatinase B ormatrix
metalloproteinase-9 (MMP-9). In physiological conditions NGAL is
detected at very low levels in several human tissues, including kidney,
heart, stomach, lungs and colon. However, the expression of NGAL be-
comes markedly induced in the post ischemic kidney and it has been
suggested that NGAL may play a role in repair and nephrogenesis [32].
Measured from baseline NGAL levels rise rapidly in both urine and
blood after renal injury. It can be measured in blood as a point of care
test, and in the urine using a standardized laboratory platform. NGAL
is a novel biomarker of Human Kidney Injury (AKI) and heart failure.
NGAL is elevated in associationwith Human Kidney Injury (patients
with AKI or who later develop AKI) in patients presenting to the emer-
gency department. The potential utility of NGAL levels in providing
early information regarding the risk of AKI development would be clin-
ically important, and could be used in a variety of clinical situations
including intensive care, emergency medicine, and renal transplanta-
tion [51]. Growing evidence suggests that NGAL may also be involved
in cell survival, inﬂammation, and matrix degradation. It seems to be
upregulated in "stressed" cells, especially in cardiomiocytes, in which
case the correlation with HF is important. Recently some studies
showed an increased serumNGAL in patient with acute and chronic HF.
In a study by Aghel A. et al, in 91 patients admitted to the hospital
with acute HF, the ones who developed worsening renal functionFig. 2. a) Kaplan–Meier plots of HF re-hospitalization free survival based on NGAL and
re-hospitalization or all-cause mortality in heart failure patients.
Data from Gallant Study Eur J Heart Fail [54].(WRF) had signiﬁcantly higher median admission serum NGAL levels
compared to those without WRF. They observed that patients with
admission NGAL values of≥140 ng/ml had a 7.4-fold chance of devel-
oping WRF [52]. NGAL is not only a risk predictor for renal injury but
an overall strong risk marker for cardiac events. The GALLANT pro-
spective trial shows that plasma NGAL is a good prognostic biomarker
of poor outcome at early stages in patients with acute heart failure
adding new information respect to BNP measurement (Fig. 2). Similar
results were found by Alvelos et al. in a 3 month follow up period [53].
An elevated serum NGAL concentration could predict a worse short
term prognosis in patients with acute HF and meanwhile suggest renal
damage in these patients. Furthermore, the ability to predict is indepen-
dent from other variables also associated with the outcome, indexes of
baseline renal function. This suggests the potential and complementary
role of NGAL respect to BNP alone in identifying patients at more
increased risk. While BNP is a marker of neuro-hormonal activation as
well as ventricular dysfunction andoverload, NGAL is amarker of kidney
injury and in particular of renal tubular damage. The combined mea-
surement of blood BNP and NGAL levels seems to increase the prog-
nostic accuracy in patients with heart failure; NGAL might have better
predictive ability compared to BNP, as it is impaired earlier and more
frequently in cases of poor prognosis. We can measure the levels of
two biomarkers at the time of discharge: high levels of NGAL could be
important for early and more frequent follow-up as well as for therapy
which safely uses diuretics [54] (Table 3).
There is an interesting relationship between serum NGAL levels
and estimated glomerular ﬁltration rates in the setting of acute HF.
Poniatowski et al. have recognized serum and urine NGAL as sensitive
early markers of renal dysfunction in patients with chronic HF and
normal serum creatinine but reduced eGFR [55]. The prognostic impact
of reduced glomerular ﬁltration rate (GFR) in chronic heart failure
(CHF) is known; the reduction of glomerular ﬁltration and increased
urinary albumin excretion (UAE) determine the outcome in patients
with chronic heart failure (HF). However renal impairment in CHF pa-
tients is not only characterised by decreased eGFR and increased UAE,
but also by the presence of tubular damage as measured by increased
urinary NGAL concentrations. In detail the extension of tubular damage
is related to the increased urinary concentrations of three urinaryB-type natriuretic peptide. b) ROC curve analysis for NGAL and BNP in predicting
Table 3
Complementary role of NGAL and BNP in patients with HF.
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(NAG) and kidney injury molecule 1 (KIM-1) in patients with CHF.
Tubular damage is also common in patientswith CHF andmildly reduced
GFR. NGAL, urinary KIM-1 and NAG show prognostic information addi-
tional to GFR [56]. Also the tubulo-interstitial injury might indicate
renal damage, even in the presence of normal glomerular ﬁltration.
Damman et al. evaluated the relationship between the individual tubular
damagemarkers, and found that all effects mortality and HF hospitaliza-
tions. Increased tubular markers were related to a poorer outcome in HF
patients even when eGFR is normal. Urinary NGAL is a good index of
tubular damage and signiﬁcantly increased in patients with chronic HF
and preserved renal function [57].
In the setting of HF, NGAL appears to be a marker of renal dysfunc-
tion and useful to identify patients at early stages of Cardio-Renal
Syndrome (CRS). Alvelos et al. have investigated the performance of
neutrophil gelatinase-associated lipocalin (NGAL) and cystatin C in the
early detection of type 1 cardio-renal syndrome in patients with acute
HF. They found a connection between NGAL and type 1 cardio-renal
syndrome. This conﬁrms the qualities of NGAL in the early recognition
of these patients. A cutoff value of 170 ng/L is able to predict straight
forward renal insufﬁciency in patients with preserved renal function
at admission [58].
Serum levels of NGAL are augmented in patients with acute and
chronic HF after myocardial infarction (MI). This value of NGAL is sig-
niﬁcantly correlated with clinical and neurohormonal deterioration.
The increase of NGAL is a result of cardiomyocytes within failing myo-
cardium, both in experimental and clinical HF. During acute or chron-
ic heart failure the blood levels of interleukin-1beta and agonists for
toll-like receptors 2 and 4 rise, components of the innate immune
system. These molecules are potent inducers of NGAL/lipocalin-2
in isolated neonatal cardiomyocytes. Clinical and experimental HF
support a role in innate immune responses in the pathogenesis of
HF [59].
5. Conclusions
NPare peptides useful in the diagnosis of HF as they addnew informa-
tion compared to traditional diagnostic tools. NPmeasurement, combined
to imaging methods, have been demonstrated to identify those subjects
with higher systolic and diastolic dysfunctions, neuro-hormonal activa-
tion and hemodynamic impairment. Thus data conﬁrm the prognostic
role of NP in acute and chronic HF. NGAL is an emerging marker able to
recognize at early stages patients with renal dysfunction. The impact of
RI in HF setting is well recognized, so the identiﬁcation of these patients
before the onset of a renal dysfunction could help physicians in strategy
treatment and risk prediction. In the future the combination of two labo-
ratorymarkers, easily available in clinical practice, could lead to better pa-
tient classiﬁcation of both patients with HF and cardio-renal syndrome as
well as to tailor treatments.References
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